Detalles de la búsqueda
1.
A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
Brain
; 142(6): 1723-1735, 2019 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31009046
2.
Clinical and cortical decline in the aphasic variant of Alzheimer's disease.
Alzheimers Dement
; 15(4): 543-552, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30765195
3.
Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Brain
; 140(3): 748-763, 2017 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28077397
4.
Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging.
Eur J Nucl Med Mol Imaging
; 44(5): 825-837, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28064343
5.
Effectiveness of Florbetapir PET Imaging in Changing Patient Management.
Dement Geriatr Cogn Disord
; 44(3-4): 129-143, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28787712
6.
Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria.
Dement Geriatr Cogn Disord
; 41(1-2): 80-92, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26745445
7.
PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.
BMC Neurol
; 14: 79, 2014 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-24716655
8.
Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline.
Alzheimer Dis Assoc Disord
; 27(1): 4-15, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23203162
9.
Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease.
Alzheimers Dement (N Y)
; 9(3): e12415, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37600216
10.
Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials.
JAMA Neurol
; 78(4): 445-453, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33587110
11.
Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer's disease pathology: a clinicopathological study.
EJNMMI Res
; 10(1): 65, 2020 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32542468
12.
Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes.
JAMA Neurol
; 77(7): 829-839, 2020 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32338734
13.
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-ß plaques: a prospective cohort study.
Lancet Neurol
; 11(8): 669-78, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22749065
14.
Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
J Nucl Med
; 53(3): 378-84, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22331215
Resultados
1 -
14
de 14
1
Próxima >
>>